[Husaeng Shinbo]
The Pan-Government Medical Device R&D Project Group (Director: Beop-min Kim; hereinafter referred to as the Project Group) is operating a Performance Promotion Pavilion (Promotional Booth, Hall D, D600) at the 39th Korea International Medical & Hospital Equipment Show (KIMES 2024), held at COEX from March 14 to 17, to promote the 10 flagship projects selected as the 2024 representative Pan-Government medical device R&D initiatives to the general public and overseas buyers.
At the Performance Promotion Pavilion, the Project Group, together with companies participating in the 10 flagship projects, is presenting posters and equipment exhibits, curated exhibition explanations, hands-on device demonstrations for the public, and real-time on-site consultations.
The 10 flagship projects are expected to contribute to:
▲ Localization of medical devices
▲ Medical public welfare (solving social issues)
▲ Industrialization of medical device exports
▲ Development of world-first medical devices
▲ Pan-Government Medical Device Full-Cycle R&D Program Achievement Promotion Pavilion |
The major companies selected for this year’s 10 Flagship Projects are Sinofex Co., Ltd., i-SENS, Inc., Todak Co., Ltd., GeneCeker Co., Ltd., Angel Robotics Co., Ltd., Curaco Co., Ltd., Medical IP Co., Ltd., JLK Inc., Curiosis, and Medipixel Co., Ltd.
First, Sinofex Co., Ltd. is expected to contribute to the localization of medical devices through the development of domestically produced equipment that includes Korea’s first artificial kidney, hemodialysis filters, and a mobile RO water purification system. i-SENS, Inc. is anticipated to contribute to addressing aging and chronic disease issues and to export industrialization by developing an ultra-compact continuous glucose monitoring system (CGMS) that integrates biosensors, electronic control, and software technologies. Todak Co., Ltd. will lead a global market worth approximately KRW 3 trillion by developing the world’s first mass-producible active implantable 32-channel cochlear implant, creating an opportunity to replace entirely imported cochlear implant products with domestically produced alternatives.
In addition, GeneCeker Co., Ltd. has worked to secure core technologies and develop diagnostic kits for lung cancer by combining next-generation sequencing (NGS) with CRISPR gene-editing technology for the first time in the world. Angel Robotics Co., Ltd. provides a full-cycle solution for gait rehabilitation training, treatment, and management through wearable walking rehabilitation robots. Curaco Co., Ltd. is expected to contribute to solving social issues by enhancing medical services, including advanced excretion care functions and integration of patient excretion data with hospital information systems, thereby improving caregiving services.
Meanwhile, Medical IP Co., Ltd. is expected to achieve commercialization in clinical settings through the world’s first development of a patient-specific extended reality (XR)-based surgical simulation medical device. JLK Inc. is expected to contribute to export industrialization by developing comprehensive AI software medical devices for the diagnosis and treatment of stroke-related cerebral infarction.
Furthermore, Curiosis is expected to realize medical device localization by developing Korea’s first digital pathology device and implementing AI-based diagnostic screening. Medipixel Co., Ltd. is expected to contribute to export industrialization by developing fully automated AI that performs cardiovascular segmentation, classification, and morphological and functional analysis for cardiovascular patients, thereby supporting real-time clinical decision-making.
The Project Group will also participate in the Global Medical Equipment Plaza (GMEP 2024), a global medical device export consultation event hosted by KOTRA, held at COEX Platz Hall from March 14 to 15.
The Project Group plans to operate showcases and participate in one-on-one business consultation meetings for outstanding projects of the Pan-Government Medical Device R&D Program, promoting them to domestic and international buyers and establishing a foothold for global expansion.
The companies selected for outstanding projects under the Pan-Government Medical Device R&D Program are BriTonics Imaging, Bioneer, CGBIO, Insung Medical, Mandro, MedInTech, AIRS Medical, MBD, Clarify, and IMGT, totaling ten companies.
BriTonics Imaging has contributed to the localization of medical devices through the development of Korea’s first brain-dedicated PET (positron emission tomography) system for age-related diseases such as dementia and Parkinson’s disease. AIRS Medical has successfully developed and exported an insulin automatic delivery system based on a world-leading artificial pancreas (AP).
MBD has improved patient benefits by developing a radiation sensitivity diagnostic kit for head and neck cancer patients, enabling prior assessment of radiotherapy effectiveness. Mandro, which won the CES Best Innovation Award this year, is expected to contribute to medical public welfare and social problem-solving through the development of domestically produced electronic prosthetic hands for people with disabilities.
MedInTech plans to realize medical device localization through the development of a flexible electronic endoscopy system for gastrointestinal use that incorporates artificial intelligence (AI) and motorization technologies. Insung Medical and CGBIO contribute to emergency medical response and health security during pandemics and infectious disease outbreaks through the localization of Korea’s first extracorporeal membrane oxygenation (ECMO) system.
Bioneer plans to obtain overseas regulatory approvals for the world’s first fully automated high-throughput molecular diagnostic PCR system integrating automatic specimen tube opening, closing, and dispensing. IMGT is developing a market-leading ultrasound-guided high-intensity focused ultrasound (HIFU) therapeutic device for integrated pancreatic cancer treatment. Clarify has verified the clinical effectiveness of its ultra-low-dose CT noise reduction and image quality enhancement solution, ClariCT·AI, and has commercialized it for the first time in the world.
Project Director Beop-min Kim stated, “In the fifth year since launch, we are seeing a wide range of achievements, including the 10 flagship projects and outstanding project outcomes,” adding, “In particular, this year’s selected flagship projects have confirmed technological advancement and the potential to secure competitiveness for domestically produced medical devices, and are expected to have significant social and economic ripple effects.”
He further emphasized, “We will actively support the discovery of outstanding research and development while creating opportunities to demonstrate the excellence of domestic products through the development of practical medical devices that deeply integrate into everyday life.”
[Husaeng Shinbo]
The Pan-Government Medical Device R&D Project Group (Director: Beop-min Kim; hereinafter referred to as the Project Group) is operating a Performance Promotion Pavilion (Promotional Booth, Hall D, D600) at the 39th Korea International Medical & Hospital Equipment Show (KIMES 2024), held at COEX from March 14 to 17, to promote the 10 flagship projects selected as the 2024 representative Pan-Government medical device R&D initiatives to the general public and overseas buyers.
At the Performance Promotion Pavilion, the Project Group, together with companies participating in the 10 flagship projects, is presenting posters and equipment exhibits, curated exhibition explanations, hands-on device demonstrations for the public, and real-time on-site consultations.
The 10 flagship projects are expected to contribute to:
▲ Localization of medical devices
▲ Medical public welfare (solving social issues)
▲ Industrialization of medical device exports
▲ Development of world-first medical devices
▲ Pan-Government Medical Device Full-Cycle R&D Program Achievement Promotion Pavilion
The major companies selected for this year’s 10 Flagship Projects are Sinofex Co., Ltd., i-SENS, Inc., Todak Co., Ltd., GeneCeker Co., Ltd., Angel Robotics Co., Ltd., Curaco Co., Ltd., Medical IP Co., Ltd., JLK Inc., Curiosis, and Medipixel Co., Ltd.
First, Sinofex Co., Ltd. is expected to contribute to the localization of medical devices through the development of domestically produced equipment that includes Korea’s first artificial kidney, hemodialysis filters, and a mobile RO water purification system. i-SENS, Inc. is anticipated to contribute to addressing aging and chronic disease issues and to export industrialization by developing an ultra-compact continuous glucose monitoring system (CGMS) that integrates biosensors, electronic control, and software technologies. Todak Co., Ltd. will lead a global market worth approximately KRW 3 trillion by developing the world’s first mass-producible active implantable 32-channel cochlear implant, creating an opportunity to replace entirely imported cochlear implant products with domestically produced alternatives.
In addition, GeneCeker Co., Ltd. has worked to secure core technologies and develop diagnostic kits for lung cancer by combining next-generation sequencing (NGS) with CRISPR gene-editing technology for the first time in the world. Angel Robotics Co., Ltd. provides a full-cycle solution for gait rehabilitation training, treatment, and management through wearable walking rehabilitation robots. Curaco Co., Ltd. is expected to contribute to solving social issues by enhancing medical services, including advanced excretion care functions and integration of patient excretion data with hospital information systems, thereby improving caregiving services.
Meanwhile, Medical IP Co., Ltd. is expected to achieve commercialization in clinical settings through the world’s first development of a patient-specific extended reality (XR)-based surgical simulation medical device. JLK Inc. is expected to contribute to export industrialization by developing comprehensive AI software medical devices for the diagnosis and treatment of stroke-related cerebral infarction.
Furthermore, Curiosis is expected to realize medical device localization by developing Korea’s first digital pathology device and implementing AI-based diagnostic screening. Medipixel Co., Ltd. is expected to contribute to export industrialization by developing fully automated AI that performs cardiovascular segmentation, classification, and morphological and functional analysis for cardiovascular patients, thereby supporting real-time clinical decision-making.
The Project Group will also participate in the Global Medical Equipment Plaza (GMEP 2024), a global medical device export consultation event hosted by KOTRA, held at COEX Platz Hall from March 14 to 15.
The Project Group plans to operate showcases and participate in one-on-one business consultation meetings for outstanding projects of the Pan-Government Medical Device R&D Program, promoting them to domestic and international buyers and establishing a foothold for global expansion.
The companies selected for outstanding projects under the Pan-Government Medical Device R&D Program are BriTonics Imaging, Bioneer, CGBIO, Insung Medical, Mandro, MedInTech, AIRS Medical, MBD, Clarify, and IMGT, totaling ten companies.
BriTonics Imaging has contributed to the localization of medical devices through the development of Korea’s first brain-dedicated PET (positron emission tomography) system for age-related diseases such as dementia and Parkinson’s disease. AIRS Medical has successfully developed and exported an insulin automatic delivery system based on a world-leading artificial pancreas (AP).
MBD has improved patient benefits by developing a radiation sensitivity diagnostic kit for head and neck cancer patients, enabling prior assessment of radiotherapy effectiveness. Mandro, which won the CES Best Innovation Award this year, is expected to contribute to medical public welfare and social problem-solving through the development of domestically produced electronic prosthetic hands for people with disabilities.
MedInTech plans to realize medical device localization through the development of a flexible electronic endoscopy system for gastrointestinal use that incorporates artificial intelligence (AI) and motorization technologies. Insung Medical and CGBIO contribute to emergency medical response and health security during pandemics and infectious disease outbreaks through the localization of Korea’s first extracorporeal membrane oxygenation (ECMO) system.
Bioneer plans to obtain overseas regulatory approvals for the world’s first fully automated high-throughput molecular diagnostic PCR system integrating automatic specimen tube opening, closing, and dispensing. IMGT is developing a market-leading ultrasound-guided high-intensity focused ultrasound (HIFU) therapeutic device for integrated pancreatic cancer treatment. Clarify has verified the clinical effectiveness of its ultra-low-dose CT noise reduction and image quality enhancement solution, ClariCT·AI, and has commercialized it for the first time in the world.
Project Director Beop-min Kim stated, “In the fifth year since launch, we are seeing a wide range of achievements, including the 10 flagship projects and outstanding project outcomes,” adding, “In particular, this year’s selected flagship projects have confirmed technological advancement and the potential to secure competitiveness for domestically produced medical devices, and are expected to have significant social and economic ripple effects.”
He further emphasized, “We will actively support the discovery of outstanding research and development while creating opportunities to demonstrate the excellence of domestic products through the development of practical medical devices that deeply integrate into everyday life.”